MedTrace Logo

Post-marketing Observational Study in Subjects With Rheumatoid Arthritis

NCT00234884 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3435

Last updated 2011-09-30

Study results available
· View outcomes & findings →

Summary

The purpose of this observational study was to observe and assess the long term use, safety, and effectiveness of adalimumab in a normal clinical setting.

Conditions

Interventions

BIOLOGICAL

adalimumab

commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)

Sponsors & Collaborators

Principal Investigators

  • Laura Redden, MD, PhD · Abbott

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Australia
  • Austria
  • Belgium
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00234884 on ClinicalTrials.gov